BIGBEAR
PHARMACEUTICAL
Encorafenib is an oral, highly selective BRAF V600 mutant kinase inhibitor, often used in combination with MEK inhibitors for enhanced efficacy.
AuthenticGuaranteeFast DeliveryPrivacy Encorafenib is a BRAF kinase inhibitor used in combination with binimetinib to treat unresectable or metastatic melanoma with BRAF V600E or V600K muta···【More】
Update: 10 Mar,2026Source: BigbearViews: 88
Braftovi is a targeted therapy specifically for BRAF V600E gene mutations. It is often used in combination with other drugs (such as cetuximab and bim···【More】
Update: 04 Mar,2026Source: BigbearViews: 92
Encorafenib is an oral small-molecule BRAF kinase inhibitor developed and manufactured by Pierre Fabre in France. It received marketing approval from ···【More】
Update: 04 Mar,2026Source: BigbearViews: 87
Encorafenib is an oral small-molecule BRAF kinase inhibitor developed and manufactured by Pierre Fabre in France. In 2018, encorafenib received market···【More】
Update: 04 Mar,2026Source: BigbearViews: 97
Encorafenib exerts its anti-tumor effect by specifically inhibiting the activity of BRAF mutant protein, thereby blocking tumor cell proliferation and···【More】
Update: 04 Mar,2026Source: BigbearViews: 97
Since its initial FDA approval in 2018 for the treatment of melanoma, encorafenib has continued to expand its indications, bringing new treatment opti···【More】
Update: 04 Mar,2026Source: BigbearViews: 98
Copyright2024@ BIGBEAR All right reserved Bigbear | Bigbear Pharmaceutical | Bigbear Laos
